Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Sleep Apnea, Obstructive

ClinicalTrials.gov lists 2,209 trials for Sleep Apnea, Obstructive or a narrower condition beneath it. Fisher and Paykel Healthcare has the most among industry and government lead sponsors, with 66.

MeSH D020181 Respiratory Tract Diseases C08 C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 46 Phase 1/2 Phase 1/2 31 Phase 2 Phase 2 80 Phase 2/3 Phase 2/3 17 Phase 3 Phase 3 83 Phase 4 Phase 4 95 Not applicable Not applicable 1,177 Observational Observational 676 Phase 1 Phase 1 46 Phase 1/2 Phase 1/2 31 Phase 2 Phase 2 80 Phase 2/3 Phase 2/3 17 Phase 3 Phase 3 83 Phase 4 Phase 4 95 Not applicable Not applicable 1,177 Observational Observational 676

Trials per phase (log scale)

2 more sections with rows

2,149 of the 2,209 trials are tagged with Sleep Apnea, Obstructive itself; the rest are tagged with a narrower condition beneath it.

Get the Sleep Apnea, Obstructive report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Sleep Apnea, Obstructive trials start? (28)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 5 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 147

1999: 3 trials (Observational 1, Phase 4 1, Phase 2/3 1) 2000: 1 trials (Phase 4 1) 2001: 3 trials (Observational 1, Not applicable 1, Phase 1 1) 2002: 3 trials (Not applicable 1, Phase 3 1, Phase 2 1) 2003: 12 trials (Observational 2, Not applicable 4, Phase 4 2, Phase 2 3, Phase 1 1) 2004: 29 trials (Observational 4, Not applicable 9, Phase 4 6, Phase 3 7, Phase 2 3) 2005: 29 trials (Observational 7, Not applicable 16, Phase 4 3, Phase 3 2, Phase 1 1) 2006: 33 trials (Observational 9, Not applicable 17, Phase 4 3, Phase 3 1, Phase 1/2 1, Phase 1 2) 2007: 53 trials (Observational 15, Not applicable 25, Phase 4 6, Phase 3 6, Phase 2 1) 2008: 65 trials (Observational 20, Not applicable 29, Phase 4 5, Phase 3 5, Phase 2/3 1, Phase 2 3, Phase 1 2) 2009: 74 trials (Observational 23, Not applicable 38, Phase 4 4, Phase 3 3, Phase 2/3 2, Phase 2 1, Phase 1/2 1, Phase 1 2) 2010: 75 trials (Observational 19, Not applicable 38, Phase 4 3, Phase 3 4, Phase 2/3 2, Phase 2 4, Phase 1/2 4, Phase 1 1) 2011: 84 trials (Observational 18, Not applicable 45, Phase 4 3, Phase 3 9, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 3) 2012: 79 trials (Observational 21, Not applicable 40, Phase 4 6, Phase 3 6, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 2013: 82 trials (Observational 17, Not applicable 53, Phase 4 7, Phase 2 1, Phase 1/2 1, Phase 1 3) 2014: 106 trials (Observational 35, Not applicable 57, Phase 4 7, Phase 3 3, Phase 2/3 1, Phase 2 2, Phase 1/2 1) 2015: 112 trials (Observational 26, Not applicable 72, Phase 4 3, Phase 3 4, Phase 2/3 1, Phase 2 4, Phase 1 2) 2016: 118 trials (Observational 32, Not applicable 75, Phase 4 4, Phase 3 2, Phase 2/3 1, Phase 2 3, Phase 1/2 1) 2017: 121 trials (Other 1, Observational 39, Not applicable 74, Phase 4 1, Phase 2 3, Phase 1/2 2, Phase 1 1) 2018: 102 trials (Other 1, Observational 38, Not applicable 54, Phase 4 1, Phase 2/3 1, Phase 2 3, Phase 1/2 2, Phase 1 2) 2019: 147 trials (Observational 53, Not applicable 76, Phase 4 6, Phase 3 2, Phase 2 2, Phase 1/2 1, Phase 1 7) 2020: 104 trials (Observational 32, Not applicable 55, Phase 4 2, Phase 2/3 1, Phase 2 10, Phase 1/2 1, Phase 1 3) 2021: 122 trials (Observational 46, Not applicable 61, Phase 4 4, Phase 2 5, Phase 1/2 2, Phase 1 4) 2022: 123 trials (Observational 33, Not applicable 71, Phase 4 5, Phase 3 3, Phase 2/3 1, Phase 2 5, Phase 1/2 2, Phase 1 3) 2023: 111 trials (Observational 40, Not applicable 47, Phase 4 4, Phase 3 6, Phase 2 8, Phase 1/2 4, Phase 1 2) 2024: 130 trials (Observational 51, Not applicable 65, Phase 4 3, Phase 3 1, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 3) 2025: 144 trials (Other 1, Observational 55, Not applicable 77, Phase 4 1, Phase 3 4, Phase 2 3, Phase 1/2 2, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 126
2025 144
2024 130
2023 111
2022 123
2021 122
2020 104
2019 147
2018 102
2017 121

Showing 10 of 28 earlier years.

Start your 14-day trial Email me all 28 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 140 trials starting in 2026 and about 140 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 174 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 1,351 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Sleep Apnea, Obstructive trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 46
Phase 1/2 31
Phase 2 80
Phase 2/3 17
Phase 3 83
Phase 4 95
Not applicable 1,177
Observational 676
Expanded access 1
Unknown 3

How many Sleep Apnea, Obstructive trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 109
Recruiting 257
Enrolling by invitation 28
Active, not recruiting 51
Available 1

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Sleep Apnea, Obstructive trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Fisher and Paykel Healthcare 66
ResMed 54
VA Office of Research and Development 24

Which drugs are being tested for Sleep Apnea, Obstructive? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
DEXMEDETOMIDINE 9
Solriamfetol 8
Armodafinil 6
Pitolisant 5
Dronabinol 5

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Acetazolamide Pill 17
Eszopiclone 3 mg QHS 11
Drug-Induced Sleep Endoscopy (Propofol) 9
Standard Care 7
Medicinal gas - oxygen (Nippon Gases 200 bar) 7

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Sleep Apnea, Obstructive trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Cardiovascular 48 2
Musculoskeletal 35 2
Band removal 33 1
Gastrointestinal 16 1
Weight loss procedure (conversion) 16 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Sleep Apnea, Obstructive? (2,631)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Continuous positive airway pressure effects on energy expenditure, intake, hormonal regulation, and body composition: a randomized trial. Sleep 2026 Yes
Mandibular Advancement Device versus CPAP in Severe Obstructive Sleep Apnea. Journal of dental research 2026 Yes
Effect of Novel Hypoglossal Stimulation on Airflow and Airway Collapsibility in OSA. Chest 2026 Yes
Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial. CNS drugs 2026 Yes
Association between obstructive sleep-disordered breathing severity and pain trajectories after adenotonsillectomy in children: a prospective cohort study. British journal of anaesthesia 2026 Yes

Showing 5 of 2,631 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages